menu
    • menu
    [{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Persavita \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant

                            Details : ANEB-001 (selonabant) is a CB1 receptor inhibitor, being evaluated for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.

                            Product Name : ANEB-001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Crinetics Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crinetics Reports Positive Topline Data from Phase 2 of Paltusotine for Carcinoid Syndrome

                            Details : Crinetics lead product candidate CRN00808 (paltusotine), an SST2 agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Carcinoid Syndrome.

                            Product Name : CRN00808

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Paltusotine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Anebulo Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects

                            Details : The funding aims to support the development of ANEB-001 (selonabant) for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.

                            Product Name : ANEB-001

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Selonabant

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Groupe Persavita

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Groupe Persavita

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persavita is Preparing for a Clinical Trial to Test its Experimental Natural Health Product in Covid-19

                            Details : Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Hea...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 20, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth